Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Walensky Defends Decision To Go Against Advisors On Pfizer COVID Booster Recommendation

Executive Summary

‘If I had been in the room, I would have voted yes,’ CDC director says of ACIP. ‘This was a scientific close call. ... And that was how my recommendations came out after listening to all of their scientific deliberations.’

You may also be interested in...



FDA Advisory Committees Continue To Come Under Congressional Scrutiny

Rep. Anna Eshoo, the ranking Democrat on the House Energy and Commerce health subcommittee suggested FDA and CDC vaccine advisory committees contributed to the public’s confusion during the pandemic response. 

With Many More COVID-19 Vaccine Changes Ahead, ACIP Expecting Fewer Public Meetings

CDC’s Advisory Committee on Immunization Practices wants a more feasible and sustainable meeting schedule in 2022, which would reduce transparency.

US CDC Panel Moves To Simplify Pfizer/BioNTech, Moderna COVID-19 Vaccine Booster Recommendations

Citing considerations of simplification, implementation and equity, Advisory Committee on Immunization Practices says everyone ages ≥50 years should get an mRNA vaccine booster dose and recommends all individuals ≥18 years have the option of getting one, without regard to occupational exposure or underlying medical conditions.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel